EXACT SCIENCES CORP
Company Information
Industry Services-Medical Laboratories
SIC Code 8071
Entity Type operating
SEC Category Large accelerated filer
Business Address 5505 ENDEAVOR LANE, MADISON, WI, 53719
Mailing Address 5505 ENDEAVOR LANE, MADISON, WI, 53719
Phone 608-284-5700
Fiscal Year End 1231
EIN 200478229
Financial Overview
FY2025
-$207.95M
Net Income
$5.93B
Total Assets
$3.15B
Stockholders' Equity
$-1.13
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
Annual Reports
10-K February 13, 2026
- Exact Sciences achieved robust 17% revenue growth to $3.2 billion, driven by strong Cologuard adoption and expanded precision oncology offerings.
- The company is making significant strategic investments ($700M R&D, $1.5B SG&A) in innovation, acquisitions, and market expansion to fuel future growth in cancer diagnostics.
Material Events
8-K Acquisition March 23, 2026
High Impact
- Exact Sciences, a leader in cancer screening (Cologuard) and diagnostics (Oncotype DX), was acquired by Abbott Laboratories in an all-cash deal.
- The acquisition valued Exact Sciences at $21 billion, with shareholders receiving $105.00 per share.
8-K Acquisition March 20, 2026
High Impact
- Abbott Laboratories is acquiring Exact Sciences Corporation, making it a fully owned subsidiary.
- Exact Sciences, known for Cologuard, leads in cancer diagnostics, offering Abbott significant market share and new technology.
8-K Acquisition February 20, 2026
High Impact
- Exact Sciences shareholders approved the $15 billion merger with Abbott Laboratories.
- Exact Sciences will gain access to Abbott's global distribution, expanded R&D, and greater capital resources.
Related Companies
Companies in the same industry (SIC: 8071)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.